Trastuzumab emtansine biosimilar (Zydus Cadila)

恩美曲妥珠单抗生物类似药（Zydus Cadila）

Report date: 2024/09/04 09:22:56

Base Information

Drug NameTrastuzumab emtansine biosimilar (Zydus Cadila)

Drug Alias NameAdo-trastuzumab emtansine (Zydus Cadila)UjviraZRC-3256

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Non-cleavable linker > MCC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > DM1 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) +[4]

Mechanisms of ActionAnti-HER2Tubulin inhibitors

TargetsReceptor protein-tyrosine kinase erbB-2Tubulin

Therapy Area/IndicationsBreast Neoplasms

Global Approved IndicationsBreast Neoplasms

Approved Indications in ChinaN/A

Original Approved Country/TerritoryIndia

Original Approved Date2021/05/24

Country/TerritoryIndia

CombinationsNo

Global Highest StatusApproved

Highest Status in ChinaN/A

Originator CompaniesZydus Cadila

China Registration ClassN/A

Develop Information

Active CompaniesZydus Cadila

Inactive CompaniesN/A

Active IndicationsBreast Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeL01XC14